Global Psoriatic Arthritis Drug Landscape Research Report 2024: Comprehensive Insights About 20+ Companies and 25+ Pipeline Drugs – ResearchAndMarkets.com
March 6, 2024DUBLIN–(BUSINESS WIRE)–The “Psoriatic Arthritis – Pipeline Insight, 2024” clinical trials has been added to ResearchAndMarkets.com’s offering.
This report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Psoriatic Arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Psoriatic Arthritis pipeline landscape is provided which includes the disease overview and Psoriatic Arthritis treatment guidelines. The assessment part of the report embraces, in depth Psoriatic Arthritis commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriatic Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Psoriatic Arthritis R&D. The therapies under development are focused on novel approaches to treat/improve Psoriatic Arthritis.
Psoriatic Arthritis Emerging Drugs Chapters
This segment of the Psoriatic Arthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Psoriatic Arthritis Emerging Drugs
Sotyktu: Bristol Myers Squibb
Sotyktu (deucravacitinib) is an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action, representing a new class of small molecules. It is the first selective TYK2 inhibitor in clinical studies across multiple immune-mediated diseases. Bristol Myers Squibb scientists designed Sotyktu to selectively target TYK2, thereby inhibiting signaling of interleukin (IL)-23, IL-12 and Type 1 interferons (IFN), key cytokines involved in the pathogenesis of multiple immune-mediated diseases.
Sotyktu achieves a high degree of selectivity by binding to the regulatory domain of TYK2, resulting in allosteric inhibition of TYK2 and its downstream functions. Sotyktu selectively inhibits TYK2 at physiologically relevant concentrations. At therapeutic doses, Sotyktu does not inhibit JAK1, JAK2 or JAK3. Currently, the drug is in the Phase III stage of its development for the treatment of Psoriasis Arthritis.
HS-10374: Hansoh BioMedical R&D Company
HS-10374 mechanism of action is to inhibit (TYK2) that is tyrosine-kinase 2. TYK2 inhibitors work by blocking the TYK2 protein and the cellular signals that run through it. Those signals can in turn activate other immune proteins and are associated with inflammation. Its route of administration is orally. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Psoriasis Arthritis.
si-544: selection
si-544, the Companys lead candidate, selectively blocks Kv1.3, a key ion channel expressed disease-associated effector memory T (TEM) cells. Kv1.3 is essential for the chronic activation and proliferation of these cells which escape the control of the immune system and become malignant. TEM cells drive inflammation in many autoimmune diseases, including atopic dermatitis, psoriasis, rheumatoid arthritis, and multiple sclerosis. Currently, the drug is in the Phase I stage of its development for the treatment of Psoriasis Arthritis.
Psoriatic Arthritis: Therapeutic Assessment
Major Players in Psoriatic Arthritis
- There are approx. 20+ key companies which are developing the therapies for Psoriatic Arthritis. The companies which have their Psoriatic Arthritis drug candidates in the most advanced stage, i.e. Phase III include, Bristol Myers Squibb.
Phases
The report covers around 25+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Psoriatic Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Psoriatic Arthritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Psoriatic Arthritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Psoriatic Arthritis drugs.
Psoriatic Arthritis Report Insights
- Psoriatic Arthritis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Psoriatic Arthritis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Players
- Pfizer
- selectION Therapeutics GmbH
- Jiangsu HengRui Medicine Co., Ltd.
- Nimbus Lakshmi, Inc.
- Hansoh BioMedical R&D Company
- Bio-Thera Solutions
- Mylan Inc.
- ACELYRIN Inc.
Key Products
- PF-06700841
- si-544
- SHR0302
- NDI-034858
- HS-10374
- BAT2506
- MYL-1401A
- ABY-035
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/v6c9p4
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900